Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04943848 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 17, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2025 to Sep 2026
    • Study completion date: Dec 2025 to Sep 2027
    v11
  2. Primary completion date: Dec 2024 to Jun 2025
    • Study completion date: Mar 2025 to Dec 2025
    • Site contacts updated at 1 of 3 sites
    v10
  3. Site contacts updated at 1 of 3 sitesv9
  4. Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Mar 2024 to Mar 2025
    v8
  5. Site contacts updated at 1 of 3 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Site contacts updated at 1 of 3 sitesv6
  2. Study description revisedv5
  3. Study sites: 2 to 3
    • Collaborators: 2 to 3
    v4
  4. Study sites: 1 to 2v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2021 to Jan 10, 2022
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 12 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
Trial Details
NCT Number NCT04943848
Lead Sponsor Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators: Dana-Farber Cancer Institute, Children's Hospital of Orange County, University of Calgary
Conditions
(from sponsor)		 Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Related terms Diffuse Intrinsic Pontine Glioma, Glioma
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov